Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
Pacific Biosciences of California (PACB) concluded the recent trading session at $1.49, signifying a -4.49% move from its prior day's close.
PACB - Pacific Biosciences of California, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$1.00
DETAILS
HIGH:
$1.00
LOW:
$1.00
MEDIAN:
$1.00
CONSENSUS:
$1.00
DOWNSIDE:
32.89%
Stock News
Here's Why You Should Add PacBio Stock to Your Portfolio Now
PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.
Pacific Biosciences of California (PACB) Stock Drops Despite Market Gains: Important Facts to Note
Pacific Biosciences of California (PACB) closed the most recent trading day at $1.66, moving 1.19% from the previous trading session.
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why
Pacific Biosciences of California (PACB) closed at $1.68 in the latest trading session, marking a -2.89% move from the prior day.
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why
Pacific Biosciences of California (PACB) closed the most recent trading day at $1.31, moving 2.96% from the previous trading session.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
PacBio Expands HiFi Sequencing Reach With New SPRQ-Nx Technology
PACB expands HiFi sequencing reach with commercial availability of SPRQ-Nx for Revio, lowering costs by about 30% and adding AI and epigenetics upgrades.
PacBio SPRQ-Nx Chemistry Now Shipping Worldwide, Enabling Sub-$300 HiFi Genomes for Large Scale Projects and AI-Enhanced Sequencing
New Revio multi-use SMRT Cells reduce sequencing costs by 30% compared to previous SPRQ chemistry while DeepConsensus improvements and expanded methylation calling increase accuracy, yield, and epigenetic insight New Revio multi-use SMRT Cells reduce sequencing costs by 30% compared to previous SPRQ chemistry while DeepConsensus improvements and expanded methylation calling increase accuracy, yield, and epigenetic insight
PacBio to Participate in the Jefferies Global Healthcare Conference
MENLO PARK, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Jefferies' Global Healthcare Conference on Thursday, June 4, 2026, at 2:00 PM ET in New York, New York.
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology
PacBio teams with Blank Bio after its $7.2M seed round, using HiFi long reads to build RNA AI models from patient tumor samples.
Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology
SAN FRANCISCO--(BUSINESS WIRE)--Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology.
HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss
Multinational study shows how one comprehensive genomic workflow and secure data collaboration may help reduce fragmented testing for couples seeking answers Multinational study shows how one comprehensive genomic workflow and secure data collaboration may help reduce fragmented testing for couples seeking answers
Pacific Biosciences of California Q1 Earnings Call Highlights
Pacific Biosciences of California NASDAQ: PACB reported first-quarter 2026 revenue of $37.2 million, roughly flat year over year, as record consumables revenue offset weaker-than-expected instrument performance amid ongoing pressure in academic and government funding, particularly in the U.S.
PACB Q1 Earnings Beat, Revenues Miss Estimates, Gross Margin Down
PacBio beats Q1 earnings estimates as consumables growth and cost cuts offset flat revenue and a weaker gross margin.
Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript
Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript
Pacific Biosciences of California (PACB) Reports Q1 Loss, Lags Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.
PacBio Announces First Quarter 2026 Financial Results
MENLO PARK, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2026.
PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now?
PACB heads into Q1 earnings with strong consumables momentum, but muted academic demand and macro pressures cloud near-term visibility.
Critical Review: Autonomix Medical (NASDAQ:AMIX) and Pacific Biosciences of California (NASDAQ:PACB)
Autonomix Medical (NASDAQ: AMIX - Get Free Report) and Pacific Biosciences of California (NASDAQ: PACB - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation. Profitability This table compares Autonomix
Price Targets
PacBio price target lowered to $1 from $1.50 at Barclays
$1.00
(was $1.45)
Barclays
PacBio price target raised to $1.70 from $1.50 at Bernstein
$1.70
(was $1.33)
Eve Burstein
·
Bernstein
PacBio price target lowered to $1.50 from $2 at Barclays
$1.50
(was $1.22)
Luke Sergott
·
Barclays
Jefferies Starts Pacific Biosciences of California (PACB) at Buy
$4.00
(was $1.79)
Tycho Peterson
·
Jefferies
PacBio price target lowered to $4 from $10 at Morgan Stanley
$4.00
(was $1.98)
Tejas Savant
·
Morgan Stanley
PacBio price target lowered to $2 from $6.50 at Piper Sandler
$2.00
(was $1.77)
David Westenberg
·
Piper Sandler
PacBio price target lowered to $2 from $3 at Barclays
$2.00
(was $1.72)
Luke Sergott
·
Barclays
Goldman Sachs Downgrades Pacific Biosciences of California (PACB) to Neutral
$2.50
(was $1.40)
Matthew Sykes
·
Goldman Sachs
PacBio price target lowered to $3.50 from $10 at Canaccord
$3.50
(was $1.40)
Kyle Mikson
·
Canaccord Genuity
Canaccord Genuity Maintains Buy on Pacific Biosciences, Raises Price Target to $14
$14.00
(was $10.80)
Canaccord Genuity
Pacific Biosciences price target raised to $7.50 from $6 at Piper Sandler
$7.50
(was $7.61)
David Westenberg
·
Piper Sandler
Pacific Biosciences price target lowered to $6 from $13 at Piper Sandler
$6.00
(was $5.84)
David Westenberg
·
Piper Sandler
PacBio Stock (PACB): $20 Price Target From Piper Sandler
$20.00
(was $14.45)
David Westenberg
·
Piper Sandler